AASLD 2005 distinguished achievement award to Dr. Jenny Heathcote
Samuel S. Lee – 29 November 2005
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women
Daniele Prati, Agostino Colli, Dario Conte, Massimo Colombo – 29 November 2005
OSTα‐OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia
Nazzareno Ballatori, Whitney V. Christian, Jin Young Lee, Paul A. Dawson, Carol J. Soroka, James L. Boyer, Michael S. Madejczyk, Na Li – 29 November 2005 – The cellular and subcellular localization and mechanism of transport of the heteromeric organic solute transporter (OST) OSTα‐OSTβ was examined in human and rodent epithelia. The two subunits of the transporter were expressed together in human small intestine, kidney, and liver, tissues that also express the apical sodium‐dependent bile acid uptake transporter ASBT (SLC10A2).
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
Francis Y. Yao, Ryutaro Hirose, Jeanne M. LaBerge, Timothy J. Davern, Nathan M. Bass, Robert K. Kerlan, Raphael Merriman, Sandy Feng, Chris E. Freise, Nancy L. Ascher, John P. Roberts – 28 November 2005 – In patients with hepatocellular carcinoma (HCC) exceeding conventional (T2) criteria for orthotopic liver transplantation (OLT), the feasibility and outcome following loco‐regional therapy intended for tumor downstaging to meet T2 criteria for OLT are unknown.
Highlights in Liver Transplantation
28 November 2005
Liver transplantation for erythropoietic protoporphyria liver disease
Brendan M. McGuire, Herbert L. Bonkovsky, Robert L. Carithers, Raymond T. Chung, Leonard I. Goldstein, John R. Lake, Anna S. Lok, Carol J. Potter, Elizabeth Rand, Michael D. Voigt, Pamela R. Davis, Joseph R. Bloomer – 28 November 2005 – In erythropoietic protoporphyria (EPP), there is excessive production of protoporphyrin, primarily in the bone marrow, resulting in increased biliary excretion of this heme precursor. Some patients will develop progressive liver disease that may ultimately require liver transplantation.
Interposition of autologous portal vein graft in left liver transplantation
Shintaro Yamazaki, Tadatoshi Takayama, Kazuto Inoue, Tokio Higaki, Masatoshi Makuuchi – 28 November 2005
Changes in liver volume from birth to adulthood: A meta‐analysis
Trevor N. Johnson, Geoffrey T. Tucker, M. Stuart Tanner, Amin Rostami‐Hodjegan – 28 November 2005 – A diversity of equations is available for the estimation of liver volume (LV), derived from studies in populations of ethnically homogeneous individuals and using a variety of methods of measurement. The aim of this study was to integrate all published pediatric data and to define a general equation for estimating LV from birth onward. Data were collated from 5,036 subjects (birth to 18 yr old).
Bacterial, mycobacterial, and protozoal infections after liver transplantation—Part I
Janis E. Blair, Shimon Kusne – 28 November 2005
High dose intravenous immunoglobulin treatment: Mechanisms of action
Peter Boros, Gabriel Gondolesi, Jonathan S. Bromberg – 28 November 2005 – Intravenous immunoglobulin (IVIg) treatment was introduced as replacement therapy for patients with antibody deficiencies, but evidence suggests that a wide range of immune‐mediated conditions could benefit from IVIg. The immunoglobulins are precipitated from human plasma by fractionation methods. In conclusion, the differences in basic fractionation methods and the addition of various modifications for purification, stabilization, and virus inactivation result in products significantly different from each other.